- Home
- SVRA vs TRIN Comparison
SVRA vs TRIN Comparison
Compare SVRA & TRIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SVRA | TRIN |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | SVRA | TRIN |
|---|---|---|
| Price | $5.15 | $14.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $7.33 | ★ $16.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 14.15% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $29.26 |
| Revenue Next Year | N/A | $6.94 |
| P/E Ratio | ★ N/A | $7.18 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $12.97 |
| 52 Week High | $7.01 | $17.20 |
Technical Indicators
Market Signals| Indicator | SVRA | TRIN |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 33.86 |
| Support Level | $5.10 | $14.38 |
| Resistance Level | $6.10 | $15.28 |
| Average True Range (ATR) | 0.29 | 0.37 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 0.98 | 6.25 |
Price Performance
Historical ComparisonAbout SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About TRIN Trinity Capital Inc.
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.